Dyvenpro Distribucion Y Venta DE Pharmaceutical Import Profile — Ecuador (DGFT 2022–2026)

Name: Dyvenpro Distribucion Y Venta DE Pharmaceutical Import Records from India — 10 Products, $16.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Dyvenpro Distribucion Y Venta DE — Pharmaceutical Importer Profile (2026) | 10 Products, $16.1M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Dyvenpro Distribucion Y Venta DE?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Wexford Laboratories Private Limited	$12.1M	876	92.3%
Sun Pharmaceutical Industries Limited	$569.0K	16	4.3%
Troikaa Pharmaceuticals Limited	$318.0K	26	2.4%
Asmoh Laboratories Limited	$129.2K	6	1.0%

Dyvenpro Distribucion Y Venta DE sources from 4 verified Indian suppliers across 261 distinct formulations. The sourcing is highly concentrated — Wexford Laboratories Private Limited accounts for 92.3% of total imports, indicating a strategic single-source relationship.

What Formulations Does Dyvenpro Distribucion Y Venta DE Import?

Formulation	Value	Ships
Amoxicillin oral suspension BP 250MG/5ML	$682.2K	29
Clarithromycin tablets USP 500MG	$529.0K	14
Acetaminophen tablets USP 500MG	$469.4K	21
Loratadine tablets USP 10MG	$397.9K	19
Amoxicillin capsules BP 500MG	$377.0K	15
Omeprazole delayed - release capsules	$361.9K	15
Ibuprofen tablets BP 400MG	$356.7K	19

What Products Does Dyvenpro Distribucion Y Venta DE Import?

Top Products by Import Value

1Ibuprofen$3.9M 2Amoxicillin$3.4M 3Loratadine$1.9M 4Enalapril$1.4M 5Ketorolac$1.1M 6Cephalexin$1.1M

Import Portfolio — Top 10 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ibuprofen	Analgesics & Antipyretics	$3.9M	77	0.7%	13
2	Amoxicillin	Antibiotics	$3.4M	67	0.5%

Key Metrics

Total Import Value$16.1M

Products10

Shipments344

Categories6

CountryEcuador

#1 Rankings1

Indian Suppliers4

Formulations261

Top Categories

Antibiotics37.5%

Analgesics & Antipyretics30.7%

Last updated: March 28, 2026

Dyvenpro Distribucion Y Venta DE — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Dyvenpro Distribución y Venta de Productos Sociedad Anónima, commonly known as Dyvenpro, is a prominent pharmaceutical importer and distributor based in Guayaquil, Ecuador. Established on November 19, 1992, the company operates within the miscellaneous nondurable goods merchant wholesalers sector. Dyvenpro is a subsidiary of Grupo Difare, a leading conglomerate in the Ecuadorian pharmaceutical industry. The company specializes in the importation, wholesale distribution, and representation of a diverse range of pharmaceutical and consumer products, including over-the-counter (OTC) medications and health-related items. With a portfolio encompassing over 500 products and 220 brands, Dyvenpro has established itself as a key player in Ecuador's pharmaceutical supply chain.

2Distribution Network

Dyvenpro's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Ecuador. The company's headquarters are located in Guayaquil, serving as the central hub for its operations. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, Dyvenpro's affiliation with Grupo Difare suggests access to an extensive infrastructure that supports nationwide distribution. This infrastructure likely includes multiple warehouses and a robust logistics system capable of handling the importation and distribution of a wide array of pharmaceutical products. The company's geographic coverage extends throughout Ecuador, ensuring that its products are accessible to a broad consumer base.

Supplier Relationship Intelligence — Dyvenpro Distribucion Y Venta DE

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Dyvenpro's sourcing strategy exhibits a significant concentration on a single supplier, Wexford Laboratories Private Limited, which accounts for 92.3% of the company's total import value from India. This heavy reliance on one supplier indicates a strategic choice aimed at achieving favorable terms, consistency in product quality, and streamlined logistics. However, such concentration also introduces potential risks, including supply chain disruptions in the event of issues with the primary supplier. The stability of this relationship is crucial for Dyvenpro's operations, and the company likely implements measures to mitigate risks associated with supplier dependency.

2Supply Chain Resilience

Dyvenpro's supply chain resilience is closely tied to its relationship with Wexford Laboratories Private Limited, the primary supplier of pharmaceutical products. The company's heavy reliance on this single supplier necessitates a robust risk management strategy to address potential disruptions. While the concentration may offer benefits such as favorable terms and consistent product quality, it also exposes Dyvenpro to risks associated with supply chain disruptions. The company likely monitors the stability and reliability of its primary supplier and may consider diversifying its supplier base to enhance supply chain resilience.

3Strategic Implications

Dyvenpro's sourcing pattern, characterized by a heavy reliance on Wexford Laboratories Private Limited, positions the company to leverage favorable terms and consistent product quality. This strategic choice may contribute to cost efficiencies and streamlined operations. However, the concentration also exposes Dyvenpro to potential risks associated with supply chain disruptions. For Indian exporters seeking to become alternative suppliers, understanding Dyvenpro's sourcing strategy is essential. Offering competitive pricing, ensuring consistent product quality, and demonstrating reliability in supply chain operations could make Indian exporters attractive partners for Dyvenpro.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Ecuador — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Ecuador

1Regulatory Authority & Framework

In Ecuador, the primary regulatory authority overseeing pharmaceutical imports is the Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (ARCSA). ARCSA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Ecuadorian market. Key legislation governing pharmaceutical imports includes the Ley Orgánica de Salud and its associated regulations, which establish the framework for the importation, registration, and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining product registration from ARCSA, which requires submission of comprehensive documentation, including evidence of product quality, safety, and efficacy.

2Import Licensing & GMP

Import licensing requirements in Ecuador mandate that all pharmaceutical products, including generics from India, must be registered with ARCSA prior to importation. This process involves submitting detailed product information, manufacturing site inspections, and compliance with Good Manufacturing Practice (GMP) standards. Ecuador recognizes GMP certificates from reputable authorities such as the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Dyvenpro and the broader Ecuadorian market must ensure that their manufacturing facilities hold valid GMP certifications from these recognized bodies. Additionally, obtaining wholesale distribution authorization from ARCSA is essential for legal distribution within Ecuador.

3Quality & Labeling

Pharmaceutical products imported into Ecuador are subject to stringent quality control measures, including batch testing and stability studies, to ensure product safety and efficacy. Labeling requirements stipulate that product labels must be in Spanish and include essential information such as product name, active ingredients, dosage form, usage instructions, and expiration date. Serialization mandates may also apply to facilitate traceability and prevent counterfeit products. Indian exporters must adhere to these quality and labeling standards to ensure compliance with Ecuadorian regulations and facilitate market acceptance.

4Recent Regulatory Changes

Between 2024 and 2026, Ecuador implemented several policy changes affecting pharmaceutical imports. These changes included updates to the Ley Orgánica de Salud, introducing more stringent requirements for product registration and importation procedures. Additionally, ARCSA enhanced its inspection protocols and increased fees associated with product registration and import licensing. These regulatory changes aim to strengthen the quality control of pharmaceutical products entering the Ecuadorian market and may impact the operational procedures of companies like Dyvenpro.

TransData Nexus Research · Ecuador regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Dyvenpro Distribucion Y Venta DE identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Dyvenpro Distribucion Y Venta DE's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 344 individual customs records matching Dyvenpro Distribucion Y Venta DE.
5.Supplier Verification: Dyvenpro Distribucion Y Venta DE sources from 4 verified Indian suppliers across 261 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

10 Products Tracked

6 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Dyvenpro Distribucion Y Venta DE

Dyvenpro Distribucion Y Venta DE — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Dyvenpro Distribucion Y Venta DE?

What Formulations Does Dyvenpro Distribucion Y Venta DE Import?

What Products Does Dyvenpro Distribucion Y Venta DE Import?

Top Products by Import Value

Import Portfolio — Top 10 by Import Value

Key Metrics

Top Categories

Dyvenpro Distribucion Y Venta DE — Corporate Profile & Information

1Company Overview

2Distribution Network

Dyvenpro Distribucion Y Venta DE Therapeutic Categories — 6 Specializations

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Dyvenpro Distribucion Y Venta DE

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Ecuador — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Dyvenpro Distribucion Y Venta DE — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Dyvenpro Distribucion Y Venta DE

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Dyvenpro Distribucion Y Venta DE

What products does Dyvenpro Distribucion Y Venta DE import from India?

Who supplies pharmaceuticals to Dyvenpro Distribucion Y Venta DE from India?

What is Dyvenpro Distribucion Y Venta DE's total pharmaceutical import value?

What therapeutic categories does Dyvenpro Distribucion Y Venta DE focus on?

Get Full Dyvenpro Distribucion Y Venta DE Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology